Biotech stocks operate under a core ethos. While there’s been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one’s health. If you can’t enjoy the fruits of your labor, then your labor will be meaningless.
That’s why healthcare as a sector performs so well. Of course, being tied to a permanently relevant narrative doesn’t guarantee any individual enterprise success. However, one thing is clear.
If you’re going to compete in an ecosystem of limited resources, you might as well do so in a burgeoning industry. Whatever might happen in the future, people will prioritize their health. That gives biotech stocks a baseline of fundamental support.
On a quantitative basis, the sector itself is massive and will likely continue expanding. Grand View Research points out that the global biotech industry reached a market size of $1.55 trillion .
By 2030, the sector could be worth $3.88 trillion, implying a compound annual growth rate (CAGR) of 13.96%.
That’s enough reason to at least research this arena. With that, below are biotech stocks to consider. Bristol-Myers Squibb (BMY) Bristol-Myers Squibb (NYSE: BMY ) offers myriad specialties, being one of the world’s top biotech stocks.
However, it commands significant relevance in the field of oncology. It offers a wide range of cancer treatments, such as Opdivo, a treatment for skin cancer. Presently, the global onc.